Autoimmune Disease Genetic Risk Test: HLA, Immune Genes, and Results

An autoimmune disease genetic risk test looks for inherited DNA differences linked to conditions in which the immune system attacks the body’s own tissues. Depending on the test, it may examine selected HLA alleles, a panel of immune-related genes, or hundreds to millions of common variants combined into a polygenic risk score. The result can show that a person has higher or lower genetic susceptibility, but it usually cannot diagnose an autoimmune disease or predict with certainty whether one will develop.

Genetic findings become most useful when they are interpreted alongside symptoms, family history, ancestry, antibody tests, inflammation markers, imaging, and other clinical information. Some HLA results have a well-defined role, such as helping rule out celiac disease or supporting an evaluation for axial spondyloarthritis. Broad consumer risk reports are less standardized and may not change medical care. Understanding what the laboratory tested—and what it did not test—is essential before acting on any result.

• A positive risk allele means increased susceptibility, not a confirmed autoimmune diagnosis.
• A negative result usually cannot exclude autoimmune disease unless the test has a specific rule-out use, such as HLA-DQ testing for celiac disease.
• Most common autoimmune conditions are polygenic, so many small genetic effects combine with environmental and immune triggers.
• No fasting is usually needed; testing commonly uses blood, saliva, or a cheek swab.
• Results should be reviewed with the ordering clinician or a genetics professional before changing screening, medication, or lifestyle plans.

Table of Contents

• What an Autoimmune Genetic Risk Test Measures
• How HLA and Other Immune Genes Affect Risk
• When Testing May Be Helpful
• Testing Methods, Samples, and the Laboratory Process
• How to Read Positive, Negative, and Uncertain Results
• Disease-Specific Examples
• Limitations, Ancestry, and Common Misunderstandings
• Next Steps After Testing

What an Autoimmune Genetic Risk Test Measures

An autoimmune genetic risk test measures inherited DNA variants associated with one or more autoimmune diseases. It is not one standardized test. The name may describe several very different products, from a single HLA marker to a genome-wide risk calculation.

The first distinction is between susceptibility testing and diagnostic genetic testing. Susceptibility testing identifies variants that shift probability. A person may carry a strong risk allele and never become ill, while another person may develop the disease without that allele. Diagnostic testing is more common for rare, single-gene immune disorders in which a pathogenic variant can explain a specific syndrome. Most rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, autoimmune thyroid disease, and celiac disease cases do not follow a simple single-gene pattern.

Common test formats include:

• Targeted HLA testing: Detects a particular allele or allele group, such as HLA-B27, HLA-DQ2/DQ8, or HLA-DRB1 variants.
• Focused variant testing: Examines selected immune-related single-nucleotide variants that have established disease associations.
• Multigene panels: Sequence genes involved in immune regulation, inflammation, or immune tolerance. These are more often used when symptoms suggest a rare monogenic autoimmune or autoinflammatory disorder.
• Polygenic risk scores: Combine the weighted effects of many common variants into a relative risk estimate.
• Genome or exome sequencing: Searches broadly for rare variants, usually when the clinical picture is unusual, severe, early in life, familial, or accompanied by immune deficiency.

A report should clearly state which genes or variants were analyzed, the testing method, the reference population, and the intended use. A vague result such as “high autoimmune risk” has little value without naming the disease, the variants included, and the evidence behind the calculation. Readers comparing tests may benefit from a general overview of a polygenic risk score test, because a PRS is interpreted differently from a single HLA allele or a rare pathogenic variant.

Genetic risk is only one layer of autoimmune susceptibility. Sex, age, infections, smoking, ultraviolet exposure, medications, hormones, microbiome changes, and other factors can influence whether immune tolerance breaks down. A DNA test therefore measures inherited predisposition; it does not measure current immune activity.

How HLA and Other Immune Genes Affect Risk

HLA genes often contribute the strongest known inherited effects in common autoimmune disease. HLA stands for human leukocyte antigen. These genes encode cell-surface proteins that present short protein fragments, called peptides, to immune cells. That process helps the immune system recognize infections, damaged cells, and abnormal cells. It also helps teach immune cells not to attack the body’s own proteins.

HLA genes sit within the major histocompatibility complex on chromosome 6. They are among the most variable genes in the human genome. Each person inherits an HLA haplotype—a linked group of HLA variants—from each parent. Because the region has extensive linkage disequilibrium, a disease association may reflect one causal allele, several nearby alleles, a regulatory variant that changes gene expression, or a combination of these factors.

HLA class I molecules, including HLA-A, HLA-B, and HLA-C, present peptides mainly to CD8 T cells. HLA class II molecules, including HLA-DP, HLA-DQ, and HLA-DR, present peptides mainly to CD4 T cells. Both classes can influence autoimmunity, but many of the strongest classic associations involve class II genes because CD4 T cells coordinate antibody production and inflammatory immune responses.

Examples include HLA-DQ2 and HLA-DQ8 in celiac disease, certain HLA-DRB1 “shared epitope” alleles in rheumatoid arthritis, HLA-DRB1*15:01 in multiple sclerosis, HLA-B27 in axial spondyloarthritis, and combinations of HLA-DR and HLA-DQ alleles in type 1 diabetes. These associations are not interchangeable. A marker linked to one autoimmune disease does not create a general diagnosis of “autoimmunity.”

Non-HLA genes also matter. Variants in PTPN22, CTLA4, IL2RA, STAT4, TYK2, TNFAIP3, IFIH1, and many other genes can influence lymphocyte signaling, cytokine pathways, antiviral responses, and immune tolerance. Most common variants have modest individual effects. Their importance emerges when many variants are considered together or when they interact with an HLA background and environmental exposures.

Rare variants can produce a different pattern. Pathogenic changes in genes such as AIRE, FOXP3, CTLA4, LRBA, STAT3, NFKB1, or genes in complement and interferon pathways may cause defined immune dysregulation syndromes. These conditions often involve early onset, multiple autoimmune organs, recurrent or unusual infections, poor growth, enlarged lymph nodes or spleen, severe eczema, chronic diarrhea, or affected relatives. In that setting, a broad genetic panel test may provide more clinically useful information than common-risk variant testing.

When Testing May Be Helpful

Testing is most helpful when the result addresses a specific clinical question. The best question is not “Do I have autoimmune genes?” Nearly everyone carries some variants associated with immune traits. A more useful question is whether a defined result can clarify diagnosis, guide follow-up, explain an unusual presentation, or inform relatives.

A clinician may consider testing in several situations:

• Symptoms and examination findings suggest a disease for which an HLA marker has established diagnostic value.
• A person has several autoimmune conditions, especially with onset in childhood or adolescence.
• Autoimmunity occurs with recurrent infections, low immunoglobulins, persistent low blood counts, severe allergies, lymphoproliferation, or inflammatory bowel symptoms.
• Several close relatives have the same unusual immune disorder or a pattern of related disorders.
• A disease appears earlier, more severely, or in a less typical form than expected.
• A specialist is deciding whether a rare immune dysregulation or autoinflammatory syndrome should be investigated.
• A research-based PRS is being used in a validated clinical program with clear action thresholds.

Testing is less likely to help when an adult without symptoms orders a broad direct-to-consumer panel and expects a yes-or-no prediction. For many autoimmune diseases, professional guidelines do not recommend population-wide genetic screening because risk estimates are not accurate enough to determine who should receive treatment or intensive surveillance. A higher score may not lead to an evidence-based preventive intervention, while a lower score can create false reassurance.

Family history remains important even when testing is available. A first-degree relative with an autoimmune disease can increase risk through shared genes and shared environment, but relatives may develop different autoimmune conditions. A clinician will usually ask which family members are affected, their age at diagnosis, organs involved, ethnic background, and whether any molecular diagnosis has already been made.

When a known pathogenic familial variant exists, targeted testing for that exact change is usually more informative and less expensive than repeating a broad panel. This approach is sometimes called cascade testing. A familial variant genetic test can determine which relatives inherited the established variant, although clinical evaluation may still be needed because penetrance can be incomplete.

Testing should not delay evaluation of active symptoms. New weakness, vision changes, chest pain, breathing difficulty, severe abdominal pain, rapidly progressive numbness, high fever, or signs of kidney injury require clinical assessment rather than a mailed genetic kit.

Testing Methods, Samples, and the Laboratory Process

Most autoimmune genetic risk tests use a blood sample, saliva, or cells collected from inside the cheek. Fasting is generally unnecessary, and medications usually do not alter inherited DNA results. Blood may be preferred when the same visit includes immune-function tests, autoantibodies, blood counts, complement studies, or inflammatory markers.

The laboratory method depends on the purpose:

Method	Typical use	Main limitation
Allele-specific PCR	Targeted HLA allele detection	Finds only the allele or allele group the assay was designed to detect
SNP microarray	Common variants and polygenic scores	May infer HLA alleles and can miss rare or population-specific variants
Next-generation sequencing panel	Rare immune dysregulation genes	May not detect every deletion, repeat, regulatory variant, or difficult HLA region change
Exome sequencing	Broad search across protein-coding genes	Limited coverage of noncoding regions and some structural variants
Genome sequencing	Broad coding and noncoding analysis	Interpretation remains difficult; availability and coverage vary

HLA testing requires special care because many alleles are similar and the region is highly polymorphic. Results may be reported at low, intermediate, or high resolution. A result such as HLA-B27 identifies an antigen or allele group, while a high-resolution result such as HLA-B*27:05 names a specific allele. The amount of detail needed depends on the clinical use. Disease-association testing may require only presence or absence of a marker, whereas transplant matching often needs high-resolution typing across several loci. More detail about the process appears in the HLA typing test overview.

Turnaround time ranges from several days for a targeted HLA assay to several weeks or months for a broad panel, exome, or genome analysis. The laboratory may request clinical information because phenotype can guide which variants are reviewed and how they are classified.

Before testing, confirm whether the laboratory is clinically accredited, whether results will enter the medical record, who will interpret them, and whether secondary findings may be reported. Broad sequencing can uncover unrelated medically significant variants, carrier status, unexpected biological relationships, or uncertain findings. Informed consent should cover these possibilities.

How to Read Positive, Negative, and Uncertain Results

The meaning of “positive” depends entirely on the test type. A positive HLA susceptibility result is not equivalent to a pathogenic variant in a disease-causing gene, and neither is equivalent to an elevated polygenic score.

Positive susceptibility allele

A report may state that an HLA allele or common variant is present. The result means that studies found the allele more often in people with a particular disease than in comparison groups. Interpretation requires both relative risk and absolute risk. An allele can multiply risk several-fold while the person’s overall chance remains low if the disease is uncommon. Conversely, a modest relative effect can matter more when baseline risk is already high because of symptoms or family history.

Many reports list an odds ratio. An odds ratio is a research measure, not a personal probability. It does not automatically account for age, sex, ancestry, smoking, antibodies, family history, or competing health factors. Laboratories that provide a calculated lifetime risk should explain the population data and calibration method used.

High or low polygenic risk score

A PRS usually places a person within a percentile relative to a reference population. The 90th percentile means the score is higher than about 90% of people in that reference group; it does not mean a 90% chance of disease. Clinical usefulness depends on how well the score predicts disease in people with similar ancestry and characteristics, whether it adds information beyond standard risk factors, and whether an action based on the score improves outcomes.

Pathogenic or likely pathogenic variant

A pathogenic variant in a relevant immune-regulation gene may support or establish a molecular diagnosis. The clinician must still check whether the person’s symptoms fit the gene, how the condition is inherited, whether one or two altered copies are required, and whether the variant arose de novo or was inherited. The result may affect treatment, monitoring, reproductive planning, and testing of relatives.

Variant of uncertain significance

A variant of uncertain significance, or VUS, means available evidence cannot classify the change as disease-causing or benign. It should not be used by itself to diagnose disease or make irreversible treatment decisions. Family studies, functional data, population databases, and future research may eventually clarify it. A clear explanation of these categories is available in the genetic variant test guide.

Negative result

A negative result may mean the tested risk allele was absent, no reportable pathogenic variant was found, or the PRS fell within a reference range. It does not necessarily mean average risk, and it rarely excludes an autoimmune disease. The test may not cover all relevant genes, variant types, or future discoveries. Symptoms and standard diagnostic testing remain more important than a negative broad risk screen.

Disease-Specific Examples

Autoimmune genetic testing has different value in different diseases. The same type of result can be useful for exclusion in one condition, supportive in another, and mostly research-oriented in a third.

Celiac disease: Most people with celiac disease carry HLA-DQ2.5, HLA-DQ2.2, or HLA-DQ8, but these HLA types are common in the general population. A positive result therefore shows genetic compatibility with celiac disease, not a diagnosis. Absence of the relevant HLA types makes celiac disease very unlikely and can be helpful when antibody or biopsy results are unclear, when a person has already stopped eating gluten, or when evaluating selected relatives. The HLA-DQ2 and HLA-DQ8 test has one of the clearest rule-out roles among autoimmune HLA tests.

Axial spondyloarthritis and ankylosing spondylitis: HLA-B27 can support evaluation in a person with inflammatory back pain, uveitis, psoriasis, inflammatory bowel disease, or a family history. Its predictive value varies widely by ancestry and local prevalence. Many healthy carriers never develop disease, and some affected people are HLA-B27 negative. Testing works best as one piece of a rheumatology assessment with examination and imaging.

Rheumatoid arthritis: Certain HLA-DRB1 alleles containing the shared epitope are associated with rheumatoid arthritis, especially anti-CCP-positive disease. They may relate to susceptibility and severity at a population level, but routine HLA genotyping is usually not needed for diagnosis. Symptoms, joint examination, rheumatoid factor, anti-CCP antibodies, inflammatory markers, and imaging are more actionable.

Type 1 diabetes: HLA-DR and HLA-DQ combinations account for a substantial portion of inherited susceptibility. Genetic risk scores can help research programs identify infants or relatives at higher risk and can assist in distinguishing type 1 diabetes from other diabetes types in selected cases. Autoantibodies and glucose testing, however, identify current autoimmune activity and metabolic disease more directly.

Multiple sclerosis: HLA-DRB1*15:01 and many non-HLA variants influence risk, but genetic testing is not a stand-alone diagnostic test. Neurologic history, examination, MRI, and cerebrospinal fluid findings carry greater clinical weight.

Systemic lupus erythematosus: Lupus has a highly polygenic architecture involving HLA and numerous immune pathways. Rare complement deficiencies or monogenic interferon and tolerance disorders can cause lupus-like disease, especially when onset is very early. In typical adult lupus, broad genetic risk tests generally remain investigational and do not replace antinuclear antibodies, disease-specific antibodies, complement levels, urine testing, and organ assessment.

These examples show why a single “autoimmune panel” cannot provide one universal interpretation. The clinical question must identify the disease and the expected role of the result.

Limitations, Ancestry, and Common Misunderstandings

The largest limitation is that association does not equal prediction. Autoimmune diseases arise through combinations of inherited susceptibility, immune history, exposures, chance, and time. Even strong HLA associations have incomplete penetrance, meaning many carriers remain healthy.

Ancestry can materially affect accuracy. HLA allele frequencies differ across populations, and a marker’s positive predictive value depends on both allele frequency and disease prevalence. Many genome-wide association studies and PRS models have overrepresented people of European ancestry. A score trained in one population may lose accuracy in another because variant frequencies and linkage patterns differ. Broad labels such as “Asian,” “Black,” “White,” or “Hispanic” are also imperfect proxies for genetic ancestry and do not capture the diversity within populations.

Other common misunderstandings include:

• “I have the gene.” Everyone has HLA and immune genes. The relevant finding is a particular allele, haplotype, or variant.
• “Positive means I will get the disease.” Most susceptibility variants are neither necessary nor sufficient to cause disease.
• “Negative means my symptoms are not autoimmune.” Most autoimmune diagnoses do not require a positive genetic marker.
• “A higher score tells me which treatment will work.” Most autoimmune PRS reports do not predict medication response.
• “All laboratories calculate the same risk.” Tests may use different variants, algorithms, ancestry references, and thresholds.
• “The result never changes.” DNA is stable, but interpretation can change as evidence, databases, and classification standards improve.

Privacy deserves attention. Genetic data can reveal information about relatives and may be stored, shared, or used for research under terms that differ among laboratories. In the United States, federal genetic nondiscrimination protections have important limits and do not cover every type of insurance. Policies vary by country and can change. People concerned about employment, life insurance, disability insurance, or long-term care insurance should obtain jurisdiction-specific advice before testing.

A result also carries emotional effects. Some people feel empowered; others become anxious, hypervigilant, or guilty about family risk. Testing is most constructive when there is a defined reason, an interpretation plan, and a realistic next step.

Next Steps After Testing

Start by obtaining the complete laboratory report rather than relying on a dashboard summary. Record the exact allele or variant, zygosity, classification, test method, genes analyzed, limitations, and reference population. Ask whether the finding was directly measured or statistically imputed from nearby markers.

Then match the result to the original clinical question:

1. Confirm the result’s category. Determine whether it is an HLA susceptibility allele, common risk variant, PRS, pathogenic variant, VUS, or negative panel.
2. Review symptoms and family history. A result has different meaning in a healthy person than in someone with inflammatory symptoms or an affected first-degree relative.
3. Use disease-specific tests when indicated. Autoantibodies, blood counts, inflammatory markers, complement levels, urine studies, imaging, biopsy, or functional immune assays may be more important than genetics.
4. Discuss action thresholds. Ask whether a guideline recommends any change in screening, referral, or treatment based on this result.
5. Consider genetics expertise. A genetic counselor, clinical geneticist, immunologist, or disease specialist can explain inheritance, penetrance, family testing, and uncertain findings.
6. Plan reanalysis when appropriate. Rare-disease panels and exome results may be reconsidered after new symptoms emerge or variant classifications change.

Do not start immunosuppressive treatment, eliminate major food groups, or undergo repeated imaging solely because of a susceptibility result. Likewise, do not dismiss persistent inflammatory symptoms because a consumer panel showed “low genetic risk.”

For a person with no symptoms and a modestly elevated PRS, standard preventive care usually remains the foundation: avoid smoking, maintain recommended vaccinations, seek evaluation for persistent symptoms, and manage established cardiovascular and metabolic risks. There is no single supplement, diet, or detoxification program proven to neutralize HLA-associated risk.

When a pathogenic variant identifies a monogenic immune disorder, the pathway is different. The care team may recommend organ-specific surveillance, infection precautions, targeted medication, immunoglobulin replacement, stem cell transplantation evaluation, or testing of relatives. Reproductive options may also be discussed. In that situation, the result is not merely a statistical risk marker; it may define a condition with specific management needs.

The most useful report is therefore one that changes understanding or care in a measured way. Genetic information can sharpen a clinical assessment, but it works best when integrated with the person’s actual health rather than treated as a forecast in isolation.

References

• Autoimmune disease: genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies? 2025 (Review)
• Exploring the HLA complex in autoimmunity: From the risk haplotypes to the modulation of expression 2024 (Review)
• Common genetic factors among autoimmune diseases 2023 (Review)
• a review of class II HLA, autoimmune disease, and the gut 2023 (Review)
• Construction and Application of Polygenic Risk Scores in Autoimmune Diseases 2022 (Review)
• GWAS and autoimmunity: What have we learned and what is still missing? 2022 (Review)

Disclaimer

Autoimmune genetic risk results do not diagnose disease and should not be used alone to start or stop treatment. Interpretation depends on the exact assay, symptoms, family history, ancestry, and other clinical tests. Discuss concerning symptoms or medically actionable findings with a qualified clinician or genetics professional.